We are a biopharmaceutical company primarily focused on the development and commercialization of proprietary biopharmaceutical products. We are developing prescription drugs for central nervous system (CNS) disorders and our current focus is the development of drugs with lower potential for abuse than currently available drugs. Our clinical-stage product currently under development is Abuse-Deterrent Amphetamine Immediate-Release, or ADAIR, a proprietary, abuse-deterrent oral formulation of immediate-release (short-acting) dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder, or ADHD, and narcolepsy.

(Note: Vallon Pharmaceuticals priced its IPO on Feb. 9, 2021, at 2.25 million shares – selling 580,000 more shares than the 1.67 million in the prospectus – at $8 each, the low end of its $8-to-$10 price range, to raise $18 million.)